[Yesterday, today and tomorrow of antiangiogenic therapy].
The role of angiogenesis in the growth of neoplasms and the factors engaged in the regulation of this process are discussed. In this paper the knowledge concerning the role of angiogenesis in the diagnosis, prognosis and treatment of malignancies is presented. The types of antiangiogenic agents used at present in oncological treatment, the first clinical experiences and the results of preclinical and clinical studies are presented. Special attention is paid to the new form of chemotherapy used in metronomic schedules and aimed at the inhibition of pathological formation of blood vessels in malignant tissues. The first clinical studies on metronomic chemotherapy in children, as well as the trials of combined antiangiogenic therapy and metronomic chemotherapy are presented.
Adamkiewicz-Drozyńska
Elzbieta
E
Klinika Pediatrii, Hematologii, Onkologii i Endokrynologii AM w Gdańsku, ul. Debinki 7, 80-211 Gdańsk, Poland. edrozd@wp.pl
Balcerska
Anna
A
Stefanowicz
Joanna
J
Bień
Ewa
E
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002648:Child; D004334:Drug Administration Schedule; D005544:Forecasting; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors